Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 93.0% | 92.9% | 26.5% | 72.8% | 56.2% | 70.2% | 89.2% | 119.3% | (384.7%) | 15.0% | 76.0% | 69.8% | (213.7%) | 639.0% | 56.3% | 126.9% | 110.4% | 102.8% | 118.2% | 90.6% |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 242.6%, based on the financial report for Sep 30, 2024 (Q3 2024). The average annual FCF to Net Income for Vertex Pharmaceuticals Incorporated have been 127.4% over the past three years, and 128.8% over the past five years.
As of today, Vertex Pharmaceuticals Incorporated's FCF to Net Income is 242.6%, which is higher than industry median of 83.9%. It indicates that Vertex Pharmaceuticals Incorporated's FCF to Net Income is Good.